The Food and Drug Administration could authorize COVID-19 boosters from Pfizer Inc. PFE, -2.96% and BioNTech SE BNTX, +4.17% for use in 16- and 17-year-olds as soon as next week as concerns rise over a new, possibly more transmissible variant, according to a person familiar with the planning.
The agency is planning to move rapidly to take action on a request by the companies to authorize boosters for 16- and-17-year-olds, according to a person familiar with the matter. So far, only people 18 years and older are eligible for boosters.
This article was originally published by Marketwatch.com. Read the original article here.
